Clinical trials: Retreatment
Kawasaki Disease
A Trial Comparing the Efficacy and Safety of Anakinra Versus Intravenous Immunoglobulin (IVIG) Retreatment, in Patients With Kawasaki Disease Who Failed to Respond to Initial Standard IVIG Treatment
Kawasaki disease (KD) is the most frequent vasculitis in younger children <5years, and the first cause of acquired ischemic myocardiopathy in childhood.
- Trial name
- ANACOMP (NCT04656184)
- Testing
- ANAKINRA, Intravenous immunoglobulin
- Where
- France
- Volunteers
- 84 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Crohn Disease
The Intensive Post Exclusive Enteral Nutrition Study
Crohn's disease (CD) is a chronic inflammatory condition with phases where the disease is active and other, where there are no symptoms.
- Trial name
- iPENS (NCT04225689)
- Testing
- CD-TREAT diet
- Where
- 5 sites in United Kingdom
- Volunteers
- 58 people, healthy volunteers welcome
- Sponsor
- NHS Greater Glasgow and Clyde
Drug Induced Hepatotoxicity, Tuberculosis
Study of Safety and Efficacy of Different Regimes of Reintroduction of Anti-TB Drugs in Anti-TB Drugs Induced Liver Damage
Purpose of the study is to evaluate the safety and efficacy of different re-introduction regimens in anti-TB drug induced liver damage. There is no consensus how best to treat such patients who developed drug induced liver damage.
- Trial name
- NCT00405301
- Testing
- Rifampicin(max dose 10 mg/kg/day), Isoniazide (max dose 5 mg/kg/day) and Pyrazinamide (max dose 25 mg/kg/day)
- Where
- 2 sites in India
- Volunteers
- 175 people
- Sponsor
- All India Institute of Medical Sciences
Apical Periodontitis
Efficacy of Different Disinfection Technologies in Molar Non-Surgical Retreatment
Post-treatment apical periodontitis is commonly associated with persistent intracanal infection following root canal treatment. Effective disinfection of the complex root canal system during nonsurgical retreatment remains…
- Trial name
- NCT07469150
- Testing
- GentleWave System, Conventional rotary instrumentation with passive ultrasonic irrigation
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- University of Alabama at Birmingham
Lupus Erythematosus, Systemic
A Study to Evaluate the Safety of Rituximab Retreatment in Subjects With Systemic Lupus Erythematosus
This is a Phase II/III, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of rituximab compared with placebo when combined with a single stable background immunosuppressive…
- Trial name
- EXPLORER (NCT00137969)
- Testing
- Rituximab, Prednisone, Acetaminophen
- Where
- 65 sites in United States, Canada
- Volunteers
- 262 people
- Sponsor
- Genentech, Inc.
Food Allergies
Master Allergen Child Nutrition. Reintroduction of Small Doses
Reintroduction of small doses of food in allergic children to lightening the elimination diet.
- Trial name
- MANOE (NCT02384707)
- Testing
- allegic food
- Where
- France
- Volunteers
- 400 people
- Sponsor
- University Hospital, Angers
Tuberculosis, Pulmonary
Novel Triple-dose Tuberculosis Retreatment Regimens: How to Overcome Resistance Without Creating More
Drug-resistance is a major challenge for tuberculosis (TB) care programs. The new WHO guideline recommends adding levofloxacin in previously treated patients with isoniazid-resistant rifampicin-susceptible TB.
- Trial name
- TriDoRe (NCT03862248)
- Testing
- 6EH³RZ, 6EHR³Z, 6EHRZLfx
- Where
- Bangladesh
- Sponsor
- Institute of Tropical Medicine, Belgium
Chronic Spontaneous Urticaria
Study of Efficacy and Safety of Ligelizumab in Chronic Spontaneous Urticaria Patients Who Completed a Previous Study With Ligelizumab
The purpose of this extension study was to establish efficacy and safety of ligelizumab. This was assessed in adult and adolescent chronic spontaneous urticaria (CSU) patients who had completed a preceding ligelizumab study and…
- Trial name
- NCT04210843
- Testing
- Ligelizumab
- Where
- 273 sites in United States, Argentina and 43 more
- Volunteers
- 1,033 people
- Sponsor
- Novartis Pharmaceuticals
Hypersensitivity, Beta Lactam Adverse Reaction
Protocol of Reintroduction of Beta-lactams in Children at Low Risk of Anaphylaxis.
The purpose of this study is to establish the rationale for the practice of performing an oral reintroduction test without previous skin tests in children at low risk of IgE-mediated reaction or drug-induced toxidermia, and to…
- Trial name
- TRO-b-lact (NCT03553251)
- Where
- France
- Volunteers
- 195 people, healthy volunteers welcome
- Sponsor
- Nantes University Hospital
Multidrug-resistant Tuberculosis, Pulmonary Tuberculosis
Novel Triple-dose Tuberculosis Retreatment Regimen
To determine if a high-dose first-line regimen is non-inferior (non-inferiority margin 10%) in terms of safety to the same regimen at regular dosing, in previously treated patients with rifampicin-susceptible recurrent…
- Conditions
- Multidrug-resistant Tuberculosis, Pulmonary Tuberculosis, Tuberculosis, Resistance to Tuberculostatic Drugs
- Trial name
- Tri-Do-Re (NCT04260477)
- Testing
- 6EH³R³Z, 6EHRZ
- Where
- Niger
- Volunteers
- 370 people
- Sponsor
- Institute of Tropical Medicine, Belgium
Malaria
Impact of Artemisinin-based Combination Therapy and Quinine on Treatment Failure and Resistance in Uncomplicated Malaria
This is a bi-centric phase IIIb, randomized, open label, 3-arm clinical trial performed to investigate the impact of retreatment with an Artemisinin-Based Combination (ACT), for example Arthemeter-Lumefantrine (AL) in Uganda (Ug)…
- Trial name
- QuinAct (NCT01374581)
- Testing
- Artemether/Lumefantrine, Artesunate/Amodiaquine, Quinine + Clindamycin
- Where
- 2 sites in Republic of the Congo, Uganda
- Volunteers
- 2,117 people
- Sponsor
- Universiteit Antwerpen
Plaque Psoriasis
A Study of JNJ-77242113 in Adolescent and Adult Participants With Moderate to Severe Plaque Psoriasis
The purpose of this study is see how effective is JNJ-77242113 in participants with moderate to severe plaque psoriasis.
- Trial name
- ICONIC-LEAD (NCT06095115)
- Testing
- JNJ-77242113
- Where
- 170 sites in United States, Argentina and 14 more
- Volunteers
- 684 people
- Sponsor
- Janssen Research & Development, LLC